Evidence map›Paper›PMID 38782774›Full record

ArticleMolecular biomedicine2024

Carcinoembryonic antigen potentiates non-small cell lung cancer progression via PKA-PGC-1ɑ axis.

Juan Lei, Lei Wu, Nan Zhang, Xudong Liu, Jiangang Zhang, Liwen Kuang, Jiongming Chen, Yijiao Chen, Dairong Li, Yongsheng Li

Abstract read
In one paragraph

Article in Molecular biomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juan LeiDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Lei WuDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Nan ZhangSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Xudong LiuSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Jiangang ZhangDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Liwen KuangSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Jiongming ChenSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Yijiao ChenSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Dairong LiDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China. lidairong@sohu.com.
Yongsheng LiDepartment of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China. lys@cqu.edu.cn.ORCID 0000-0003-2175-9449

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 81920108027Natural Science Foundation of chongqing cstc2020jcyj-msxmX0516Young and Middle-Aged Medical Excellence Team Young and Middle-Aged Medical Excellence Team
6 · The paper itself

Abstract

Carcinoembryonic antigen (CEA) is a tumor-associated antigen primarily produced by tumor cells. It has been implicated in various biological processes such as cell adhesion, proliferation, differentiation, and metastasis. Despite this, the precise molecular mechanisms through which CEA enhances tumor cell proliferation remain largely unclear. Our study demonstrates that CEA enhances the proliferation and migration of non-small cell lung cancer (NSCLC) while also inhibiting cisplatin-induced apoptosis in NSCLC cells. Treatment with CEA led to an increase in mitochondrial numbers and accumulation of lipid droplets in A549 and H1299 cells. Additionally, our findings indicate that CEA plays a role in regulating the fatty acid metabolism of NSCLC cells. Inhibiting fatty acid metabolism significantly reduced the CEA-mediated proliferation and migration of NSCLC cells. CEA influences fatty acid metabolism and the proliferation of NSCLC cells by activating the PGC-1α signaling pathway. This regulatory mechanism involves CEA increasing intracellular cAMP levels, which in turn activates PKA and upregulates PGC-1α. In NSCLC, inhibiting the PKA-PGC-1α signaling pathway reduces both fatty acid metabolism and the proliferation and migration induced by CEA, both in vitro and in vivo. These results suggest that CEA contributes to the promotion of proliferation and migration by modulating fatty acid metabolism. Targeting CEA or the PKA-PGC-1ɑ signaling pathway may offer a promising therapeutic approach for treating NSCLC.

Indexed as

Carcinoembryonic AntigenCarcinoma, Non-Small-Cell LungCell MovementCell ProliferationCyclic AMP-Dependent Protein KinasesLung NeoplasmsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSignal TransductionAnimalsApoptosisCell Line, TumorDisease ProgressionFatty AcidsHumansMiceCarcinoembryonic AntigenCyclic AMP-Dependent Protein KinasesFatty AcidsPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanAnti-tumor therapyCarcinoembryonic antigen (CEA)Fatty acid metabolismNon-small cell lung cancerPGC-1α

Identifiers

PMID38782774
PMCPMC11116303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.